Unaudited Interim Results For The Six Months Ended 31 December 2023
4 April 2024
Interim Report and Financial Statements for the 6 months to 31 December 2023 To download this report as…
Stay up to date with our recent press releases, Shareholder meetings and any investor related announcements.
4 April 2024
Interim Report and Financial Statements for the 6 months to 31 December 2023 To download this report as…
10 November 2023
Bioventix plc (AIM: BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for…
30 October 2023
Director’s report and financial statements for the year ended 30th June 2023. To download this report as a PDF…
3 April 2023
Interim Report and Financial Statements for the 6 months to 31 December 2022 To download this report as…
8 December 2022
Bioventix plc (“Bioventix” or the “Company”) Result of AGM Bioventix plc (AIM: BVXP) announces that at its Annual…
8 November 2022
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications…
24 October 2022
Director’s report and financial statements for the year ended 30th June 2022. To download this report as a PDF…
28 March 2022
Interim Report and Financial Statements for the 6 months to 31 December 2021 To download this report as…
10 December 2021
Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting (“AGM”), all resolutions put to shareholders were duly…
11 November 2021
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications…
18 October 2021
Director’s report and financial statements for the year ended 30th June 2021. To download this report as a PDF…
29 March 2021
Unaudited interim results for the six months ended 31st December 2020